Literature DB >> 14615113

Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana.

B Mosimaneotsile1, E A Talbot, T L Moeti, N M Hone, G Moalosi, H J Moffat, E J Lee, T A Kenyon.   

Abstract

To exclude tuberculosis, WHO/UNAIDS recommends considering medical history, symptom screen, and chest radiograph before starting tuberculosis prevention in people infected with HIV. The value of a chest radiograph for this purpose is unknown. We prospectively assessed 935 HIV-infected outpatients seeking isoniazid preventive therapy. Of 935 patients, 692 (74%) had no signs or symptoms of tuberculosis. Of these 692, 123 (18%) were lost during the chest radiograph process, and one (0.2%) of the remaining 563 was diagnosed with tuberculosis on the basis of the chest radiograph. A screening chest radiograph should not be required routinely for asymptomatic people taking isoniazid as preventive treatment in settings able to screen for signs and symptoms of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615113     DOI: 10.1016/s0140-6736(03)14745-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Impact of a training course on the quality of chest radiography to diagnose pulmonary tuberculosis.

Authors:  A Ohkado; P Luna; A Querri; M Mercader; S Yoshimatsu; L Coprada; R Bañares; A M C Garfin; T Date
Journal:  Public Health Action       Date:  2015-03-21

2.  Impact of mycobacterial culture among HIV-infected adults with presumed TB in Uganda: a prospective cohort study.

Authors:  F C Semitala; L H Chaisson; S den Boon; N Walter; A Cattamanchi; M Awor; J Katende; L Huang; M Joloba; H Albert; M R Kamya; J L Davis
Journal:  Public Health Action       Date:  2015-05-08

3.  Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis.

Authors:  Krishna K Singh; Yuxin Dong; John T Belisle; Jeffrey Harder; Vijay K Arora; Suman Laal
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

4.  New regimens to prevent tuberculosis in adults with HIV infection.

Authors:  Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

5.  Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis.

Authors:  Krishna K Singh; Yuxin Dong; Sai A Patibandla; David N McMurray; Vijay K Arora; Suman Laal
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 6.  Active case finding of tuberculosis: historical perspective and future prospects.

Authors:  J E Golub; C I Mohan; G W Comstock; R E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  2005-11       Impact factor: 2.373

Review 7.  Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.

Authors:  Christopher Akolo; Florence Bada; Evaezi Okpokoro; Ogochukwu Nwanne; Sharon Iziduh; Eno Usoroh; Taofeekat Ali; Vivian Ibeziako; Olanrewaju Oladimeji; Michael Odo
Journal:  World J Virol       Date:  2015-05-12

8.  Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana.

Authors:  Taraz Samandari; David Bishai; Michiel Luteijn; Barudi Mosimaneotsile; Oaitse Motsamai; Maarten Postma; Gijs Hubben
Journal:  Am J Respir Crit Care Med       Date:  2010-12-10       Impact factor: 21.405

9.  Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV.

Authors:  R Dawson; P Masuka; D J Edwards; E D Bateman; L-G Bekker; R Wood; S D Lawn
Journal:  Int J Tuberc Lung Dis       Date:  2010-01       Impact factor: 2.373

Review 10.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.